Curis Closes $80.8 Million PIPE Financing to Advance Emavusertib Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy CRIS?
Source: PRnewswire
- Successful Financing: Curis, Inc. has successfully closed a PIPE financing round, securing up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will provide crucial funding for the development of its drug emavusertib, supporting the company's ongoing growth in the biotechnology sector.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis and its development pipeline, thereby enhancing the company's capital foundation.
- Drug Development Progress: Emavusertib, a small molecule IRAK4 and FLT3 inhibitor, is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma and has received Orphan Drug Designation from the FDA, indicating its potential market value in the treatment landscape.
- Future Development Plans: Curis plans to continue advancing emavusertib in both monotherapy and combination treatments for acute myeloid leukemia, and with this financing, the company expects to accelerate its clinical development process, enhancing its competitiveness in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRIS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRIS
Wall Street analysts forecast CRIS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.555
Low
5.00
Averages
11.00
High
17.00
Current: 0.555
Low
5.00
Averages
11.00
High
17.00
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Curis Reports Significant Q4 2025 Profit Improvement
- Quarterly Profit Growth: Curis reported a net income of $19.4 million for Q4 2025, a significant turnaround from a net loss of $9.6 million in Q4 2024, indicating substantial progress in the company's financial health.
- R&D Expense Reduction: Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, reflecting effective cost control measures that enhance overall profitability.
- Strong Cash Position: As of December 31, 2025, Curis's cash and cash equivalents are expected to support operations into the second half of 2027, demonstrating robust financial management that secures funding for future R&D and market expansion.
- Clinical Trial Progress: Curis is actively advancing its TakeAim Lymphoma study and has begun activating clinical sites in the US and Europe, with preliminary data expected at the 2026 ASH Annual Meeting, potentially laying a foundation for future market performance.
See More
Curis, Inc. Q4 2025 Earnings Call Insights
- Financial Improvement: Curis reported a net income of $19.4 million for Q4 2025, translating to earnings of $1.23 per share, a significant turnaround from a net loss of $9.6 million in the same quarter of 2024, primarily driven by a one-time noncash gain of $27.2 million.
- Clinical Trial Progress: The TakeAim Lymphoma study in primary CNS lymphoma (PCNSL) is on track for full enrollment within 12 to 18 months, which will support future regulatory submissions and enhance the company's competitive position in oncology.
- New Research Initiation: Curis is activating sites in the U.S. and Europe for a proof-of-concept study in chronic lymphocytic leukemia (CLL), with initial data expected at the ASH Annual Meeting in December, providing new opportunities for expansion in hematologic cancer treatment.
- Resource Prioritization Shift: Management has indicated that future resources will be prioritized for PCNSL and CLL studies, while activities related to acute myeloid leukemia (AML) will be deprioritized, reflecting a strategic adjustment in light of limited funding.
See More
Curis (CRIS) Q4 2025 Earnings Call Transcript
See More
Curis Reports 2025 Financial Results and Financing Progress
- Financing Progress: Curis closed a private placement in January 2026 with gross proceeds of up to $80.8 million, including initial proceeds of approximately $20.2 million, which includes three series of exercisable warrants, indicating the company's proactive approach in capital markets.
- Financial Performance: Curis reported a net loss of $7.6 million for 2025, or $0.58 per share, a significant improvement compared to a net loss of $43.4 million in 2024, demonstrating progress in cost control and operational efficiency.
- R&D Expense Reduction: Research and development expenses decreased to $28.3 million in 2025 from $38.6 million in 2024, primarily due to lower employee-related, clinical, and consulting costs, reflecting optimization in resource allocation.
- Cash Flow Outlook: As of December 31, 2025, Curis had $5.1 million in cash and cash equivalents, and with the financing received in early 2026, the company expects to sustain operations into the second half of 2027, showcasing a cautious strategy in financial management.
See More
Curis Reports Q4 Earnings with Mixed Results
- Earnings Beat: Curis reported a Q4 GAAP EPS of $1.23, exceeding expectations by $1.67, indicating an unexpected strength in profitability despite overall revenue decline.
- Significant Revenue Drop: The company posted revenue of $1.14 million, a 66% year-over-year decrease, missing market expectations by $2.11 million, reflecting challenges in business performance and weak market demand.
- Private Placement Announcement: Curis has priced an $80.8 million private placement aimed at enhancing liquidity and capital structure to support future R&D and operational needs, despite the current poor performance.
- Cautious Market Reaction: Due to the significant revenue decline and uncertainty about the future, the market's reaction to Curis has been cautious, potentially impacting its stock performance and investor confidence.
See More
Curis Scheduled to Announce Q4 Earnings Results
- Earnings Announcement Schedule: Curis is set to announce its Q4 earnings on March 19th after market close, with a consensus EPS estimate of -$0.43, reflecting a significant year-over-year improvement of 65.6%, indicating efforts to enhance profitability.
- Revenue Expectations: Analysts project Curis's Q4 revenue to be $3.25 million, representing a 3.0% decline year-over-year, which highlights challenges the company faces in a competitive market and may impact investor confidence.
- Private Placement Details: Curis has recently completed an $80.8 million private placement, which will provide essential funding for its operations and R&D, thereby strengthening its competitive position in the biopharmaceutical sector.
- Historical Financial Data: Curis's historical financial data shows significant volatility in performance over recent quarters, prompting investors to closely monitor the upcoming earnings report to assess future growth potential.
See More
Curis Reports Significant Q4 2025 Profit Improvement
- Quarterly Profit Growth: Curis reported a net income of $19.4 million for Q4 2025, a significant turnaround from a net loss of $9.6 million in Q4 2024, indicating substantial progress in the company's financial health.
- R&D Expense Reduction: Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, reflecting effective cost control measures that enhance overall profitability.
- Strong Cash Position: As of December 31, 2025, Curis's cash and cash equivalents are expected to support operations into the second half of 2027, demonstrating robust financial management that secures funding for future R&D and market expansion.
- Clinical Trial Progress: Curis is actively advancing its TakeAim Lymphoma study and has begun activating clinical sites in the US and Europe, with preliminary data expected at the 2026 ASH Annual Meeting, potentially laying a foundation for future market performance.
See More
Curis, Inc. Q4 2025 Earnings Call Insights
- Financial Improvement: Curis reported a net income of $19.4 million for Q4 2025, translating to earnings of $1.23 per share, a significant turnaround from a net loss of $9.6 million in the same quarter of 2024, primarily driven by a one-time noncash gain of $27.2 million.
- Clinical Trial Progress: The TakeAim Lymphoma study in primary CNS lymphoma (PCNSL) is on track for full enrollment within 12 to 18 months, which will support future regulatory submissions and enhance the company's competitive position in oncology.
- New Research Initiation: Curis is activating sites in the U.S. and Europe for a proof-of-concept study in chronic lymphocytic leukemia (CLL), with initial data expected at the ASH Annual Meeting in December, providing new opportunities for expansion in hematologic cancer treatment.
- Resource Prioritization Shift: Management has indicated that future resources will be prioritized for PCNSL and CLL studies, while activities related to acute myeloid leukemia (AML) will be deprioritized, reflecting a strategic adjustment in light of limited funding.
See More
Curis (CRIS) Q4 2025 Earnings Call Transcript
See More
Curis Reports 2025 Financial Results and Financing Progress
- Financing Progress: Curis closed a private placement in January 2026 with gross proceeds of up to $80.8 million, including initial proceeds of approximately $20.2 million, which includes three series of exercisable warrants, indicating the company's proactive approach in capital markets.
- Financial Performance: Curis reported a net loss of $7.6 million for 2025, or $0.58 per share, a significant improvement compared to a net loss of $43.4 million in 2024, demonstrating progress in cost control and operational efficiency.
- R&D Expense Reduction: Research and development expenses decreased to $28.3 million in 2025 from $38.6 million in 2024, primarily due to lower employee-related, clinical, and consulting costs, reflecting optimization in resource allocation.
- Cash Flow Outlook: As of December 31, 2025, Curis had $5.1 million in cash and cash equivalents, and with the financing received in early 2026, the company expects to sustain operations into the second half of 2027, showcasing a cautious strategy in financial management.
See More
Curis Reports Q4 Earnings with Mixed Results
- Earnings Beat: Curis reported a Q4 GAAP EPS of $1.23, exceeding expectations by $1.67, indicating an unexpected strength in profitability despite overall revenue decline.
- Significant Revenue Drop: The company posted revenue of $1.14 million, a 66% year-over-year decrease, missing market expectations by $2.11 million, reflecting challenges in business performance and weak market demand.
- Private Placement Announcement: Curis has priced an $80.8 million private placement aimed at enhancing liquidity and capital structure to support future R&D and operational needs, despite the current poor performance.
- Cautious Market Reaction: Due to the significant revenue decline and uncertainty about the future, the market's reaction to Curis has been cautious, potentially impacting its stock performance and investor confidence.
See More
Curis Scheduled to Announce Q4 Earnings Results
- Earnings Announcement Schedule: Curis is set to announce its Q4 earnings on March 19th after market close, with a consensus EPS estimate of -$0.43, reflecting a significant year-over-year improvement of 65.6%, indicating efforts to enhance profitability.
- Revenue Expectations: Analysts project Curis's Q4 revenue to be $3.25 million, representing a 3.0% decline year-over-year, which highlights challenges the company faces in a competitive market and may impact investor confidence.
- Private Placement Details: Curis has recently completed an $80.8 million private placement, which will provide essential funding for its operations and R&D, thereby strengthening its competitive position in the biopharmaceutical sector.
- Historical Financial Data: Curis's historical financial data shows significant volatility in performance over recent quarters, prompting investors to closely monitor the upcoming earnings report to assess future growth potential.
See More
